Market Place
Sourcing Support
Positive Nizubaglustat Phase 2 Data Presented For NPC And GM2
10 Sep 2024 //
BUSINESSWIRE
Azafaros Reports Positive Phase 2 Data For Nizubaglustat In GM2 And NPC
16 Jul 2024 //
BUSINESSWIRE
Azafaros announces completion of 12-week Phase 2 RAINBOW study
12 Mar 2024 //
GLOBENEWSWIRE
Azafaros to present data from PRONTO study in GM1 and GM2 gangliosidoses
22 Jan 2024 //
GLOBENEWSWIRE
Azafaros™ Phase 2 RAINBOW study, evaluating nizubaglustat is now fully enrolled
11 Dec 2023 //
GLOBENEWSWIRE
Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study
08 Jun 2023 //
BUSINESSWIRE
Azafaros Appoints Chief Operating Officer and Head of Finance
20 Mar 2023 //
BUSINESSWIRE
Azafaros Receives Regulatory Designations for AZ-3102 from FDA, EMA and MHRA
21 Feb 2023 //
BUSINESSWIRE
Azafaros Strengthens Medical and Scientific Management Team
09 Jan 2023 //
BUSINESSWIRE
Azafaros Receives FDA`s IND Clearance and Fast Track Designation for AZ-3102
05 Jan 2023 //
BUSINESSWIRE
Azafaros Announces FDA Grant of ODD for AZ-3102 in Niemann-Pick Disease
24 Mar 2022 //
BUSINESSWIRE
Azafaros Presents Positive Clinical and Preclinical Data for AZ-3102
14 Feb 2022 //
BUSINESSWIRE
Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis
01 Feb 2022 //
BUSINESSWIRE
Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer
30 Jun 2021 //
BUSINESSWIRE
Azafaros Enters Clinical Stage With AZ-3102, an Oral Small Molecule
05 Apr 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.